Endologix Reports Positive Results from Global ENCORE Analysis with Polymer Endovascular Aneurysm Repair (EVAR) Using Ovation Abdominal Stent Graft Systems
Company to Host Investor Conference Call on
ENCORE is a pooled, retrospective analysis of six prospectively enrolled
clinical trials and registries of Ovation Abdominal Stent Graft Systems
encompassing 1,296 patients, 160 centers and 339 investigators in the
Median follow up across all studies was 883 days (range 30 days - 5 years). At five years, the ENCORE analysis included the following results for Ovation based on the available data:
99.1% freedom from
- 99.0% freedom from reintervention for Type 1a endoleak
- 99.7% freedom from rupture
- 99.2% freedom from conversion
- 96.4% freedom from all device-related reintervention
"With ENCORE, our objective was to conduct a rigorous, global evaluation
of the available Polymer EVAR clinical data, which includes nearly 1,300
patients, and to share the consolidated results with physicians
The Company will host a conference call at 8:30 a.m. ET on
The conference call will also be webcast and can be accessed from the "Investors" section of the Company's website at www.endologix.com. The webcast replay of the call will be available at the same site, approximately one hour after the end of the call.
A recording of the call will also be available from
Cautions Regarding Forward-Looking Statements
Except for historical information contained herein, this press
release contains forward-looking statements within the meaning of the
Private Securities Litigation Reform Act of 1995. These forward-looking
statements generally can be identified by the use of words such as
"anticipate," "expect," "could," "may," "will," "believe," "estimate,"
"forecast," "goal," "project," "continue," "outlook," "guidance,"
"future," other words of similar meaning and the use of future dates.
Forward-looking statements used in this press release include, but are
not limited to, statements regarding the ENCORE analysis and
presentation of further results, the accuracy of which are necessarily
subject to risks and uncertainties that may cause future events to
differ materially and adversely from the statements contained herein.
Some of the potential risks and uncertainties that could cause actual
results to differ materially and adversely include Endologix's ability
to continue to follow-up on patients in the ENCORE analysis and to
provide further ENCORE analyses. Undue reliance should not be placed
upon the forward-looking statements contained in this press release,
which speak only as of the date of this press release.
News Provided by Acquire Media